Amgen CEO Teases 2026 As ‘Springboard Year’ After 14 Blockbusters And 18 Record Products

The company’s strong product performance helped offset pricing pressure and biosimilar competition across parts of its portfolio.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin